Beijing Scitop Bio-tech Co (300858) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥84.99 million, up 9.51% year-over-year, while net profit attributable to shareholders fell 26.46% to ¥14.95 million.

• Cash flow from operating activities improved significantly to ¥7.15 million from a negative ¥0.53 million in Q1 2025.

• The company announced a share repurchase plan using its own funds, with a total amount between ¥100 million and ¥150 million.

Financial highlights

• Operating income: ¥84.99 million (up 9.51% YoY).

• Net profit attributable to shareholders: ¥14.95 million (down 26.46% YoY).

• Basic and diluted EPS: ¥0.06 (down 25% YoY).

• Total assets at period end: ¥2.03 billion (up 0.42% from year-end 2025).

• Net cash from operating activities: ¥7.15 million (up 1,449.76% YoY).

Outlook and guidance

• The company plans to repurchase shares for employee incentive or stock ownership plans, signaling confidence in future prospects.